Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Cardiovascular Medicine

Myocardial Infarction

This presentation may include discussion of commercial products and services. Significant progress has been made in the primary and secondary prevention of myocardial infarction (MI). Nevertheless, there has been...
CME credit is no longer available for this conference.

Course Authors

Richard Josephson, M.S., M.D., and Sri K. Madan Mohan, M.D.

Dr. Josephson is Professor of Medicine Case Western Reserve University School of Medicine. Director Cardiac Intensive Care Unit and Director Cardiovascular & Pulmonary Rehabilitation at Harrington Heart & Vascular Institute and Dr. Mohan is Assistant Professor of Medicine, 
Chief Quality Officer and 
Program Director, 
Harrington Heart & Vascular Institute
, Case Western University School of Medicine, Cleveland, OH.

Within the past 12 months, Drs. Josephson and Mohan report no commercial support.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Discuss the role of medications and therapies in the post-MI patient

  • Counsel the patient regarding post-MI risk and activity

  • Identify and address the problem of non-adherence to medications.

 

TERMS AND CONDITIONS

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Current Management of Hypertension

In 1945, when Franklin D. Roosevelt died of a stroke, little did his physicians know that his long-standing hypertension, with recorded systolic blood pressures as high as 300, had a… major role in his untimely death at the age of 63. The Framingham Heart Study, started in 1949, provided the first insights into the link between elevated blood pressure and cardiovascular disease, with its findings first published in 1961. Since then, numerous studies have provided valuable information about hypertension…
Authors: Aditya Khetan, M.B.B.S., Richard A Josephson, M.S., M.D. and Sri Krishna Madan Mohan M.B.B.S.
Estimated Time: 1 Hour
View Course
More

Management of Non-Valvular Atrial Fibrillation – The New Era of Oral Anticoagulants

This presentation may include discussion of commercial products and services. Atrial fibrillation (AF) is defined as a tachyarrhythmia of supraventricular origin leading to deterioration in mechanical function of the… atrium. An electrocardiogram (ECG) shows fibrillatory waves varying in amplitude, shape and timing instead of P waves. These fibrillatory waves lead to an irregular rapid ventricular response. AF can occur with other atrial arrhythmias of which atrial flutter is the most common entity. The most important feature which distinguishes…
Authors: Muhib Khan, M.D., and Karen Furie, M.D., M.P.H.
Estimated Time: 2 Hours
View Course
More

Current Management of Acute Decompensated Heart Failure

The prevalence of heart failure (HF) in the U.S. exceeds six million people. This number will continue to grow with the aging population and increased incidence of… risk factors such as obesity and diabetes. In addition to physical limitations, individuals with HF have a significantly reduced life expectancy even in this era of modern medical therapies. HF hospitalization is one of the strongest predictors of mortality in patients with cardiomyopathy. Up to 30% of those…
Authors: Joel Schilling, M.D., Ph.D.
Estimated Time: 1 Hour
View Course
More

Pharmacological Therapy of Cardiac Arrhythmias: Atrial Fibrillation, Current Treatment and Novel Agents

Cardiac arrhythmias may be seen in individuals with known cardiovascular disease (i.e., coronary artery disease (CAD) or valvular abnormalities) or even in those without known cardiac illnesses. The spectrum… of cardiac arrhythmias varies between more self-limited or minimally symptom atic findings such as palpitations, which may be associated with premature supraventricular or ventricular beats that many experience, to the more worrisome ventricular fibrillation, a known cause of sudden cardiac arrest for which emergency cardiac resuscitation is required. Usually, cardiac arrhythmias…
Authors: Mohan N. Viswanathan, M.D.
Estimated Time: 1 Hour
View Course
More

Cardiac Vagal Neurostimulation for Ventricular Rate Control During Atrial Fibrillation

Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, with an estimated 2.3 million Americans having AF. The prevalence of AF increases with age, reaching… about 9% for those older than 80. Due to the aging of population, the number of AF patients is estimated to increase 2.5 times during the next 50 years. AF accounted for approximately one-third of all hospitalizations with a cardiac rhythm disturbance, and significantly…
Authors: Youhua Zhang, M.D., Ph.D., and Todor N. Mazgalev, Ph.D.
Estimated Time: 1 Hour
View Course
More

Suppression of the Renin-Angiotensin-Aldosterone System

"It is not the answers that enlighten, but the questions." - Ionesco The renin-angiotensin system (RAS) is a major hormonal autocrine/paracrine system that under normal conditions contributes to the regulation of… cardiovascular and renal functions. However, under pathologic condition this system is involved in mechanisms leading to enhanced vasoconstriction, sodium retention, inflammation, matrix formation and cellular hypertrophy. Figure 1. The Renin-Angiotension System. Angiotensin II (Ang II), the major effector peptide of the…
Authors: Samer Ellahham, M.D. and Helmy M. Siragy, M.D.
Estimated Time: 1 Hour
View Course
More